Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Stopped No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.

Conditions

• Head and Neck Cancer

Interventions

• DRUG: Xevinapant
• DRUG: Cisplatin
• RADIATION: intensity-modulated radiation therapy (IMRT)

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]